Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43865   clinical trials with a EudraCT protocol, of which   7286   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-001924-16
    Sponsor's Protocol Code Number:FDY-5301-302
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2021-12-07
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2021-001924-16
    A.3Full title of the trial
    IOCYTE AMI-3: A Phase 3, Randomized, Double-Blind,
    Placebo-Controlled, Multicenter Study of Intravenous
    FDY-5301 in Patients with an Anterior ST-Elevation
    Myocardial Infarction
    IOCYTE AMI-3 Estudio de fase 3, multicéntrico, aleatorizado, doble ciego y
    controlado con placebo de FDY-5301 intravenoso en pacientes con infarto de miocardio con elevación del segmento ST anterior
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of IV FDY-5301 in patients with a myocardial infarction (STEMI)
    Un estudio de fase 3, aleatorizado, doble ciego, controlado con placebo y multicéntrico de IV FDY-5301 en pacientes con un infarto de miocardio (IMEST)
    A.3.2Name or abbreviated title of the trial where available
    IOCYTE AMI-3
    IOCYTE AMI-3
    A.4.1Sponsor's protocol code numberFDY-5301-302
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT04837001
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorFaraday Pharmaceuticals, Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportFaraday Pharmaceuticals, Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationMedpace Inc.
    B.5.2Functional name of contact pointMedpace Regulatory Submissions
    B.5.3 Address:
    B.5.3.1Street Address5400 Medpace Way
    B.5.3.2Town/ cityCincinnati
    B.5.3.3Post codeOH 45227
    B.5.3.4CountryUnited States
    B.5.6E-mailregsubmissions@medpace.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameFDY-5301
    D.3.2Product code FDY-5301
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNSODIUM IODIDE
    D.3.9.1CAS number 7681-82-5
    D.3.9.2Current sponsor codeFDY-5301
    D.3.9.3Other descriptive nameSODIUM IODIDE
    D.3.9.4EV Substance CodeSUB15295MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number7.2
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection
    D.8.4Route of administration of the placeboIntravenous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Anterior ST-Elevation Myocardial Infarction
    Infarto de miocardio con elevación del segmento ST (IMEST) anterior
    E.1.1.1Medical condition in easily understood language
    Myocardial Infarct (heart attack)
    Infarto de miocardio (ataque cardíaco)
    E.1.1.2Therapeutic area Diseases [C] - Cardiovascular Diseases [C14]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10064346
    E.1.2Term STEMI
    E.1.2System Organ Class 100000004849
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To assess the effect of FDY-5301 on cardiovascular mortality and heart failure events in subjects with an anterior STEMI undergoing pPCI.
    Evaluar el efecto de FDY-5301 sobre la mortalidad de origen cardiovascular y los episodios de insuficiencia cardíaca en sujetos con IMEST anterior sometidos a una ICPp.
    E.2.2Secondary objectives of the trial
    To assess the effect of FDY-5301 on other clinical outcomes such as all-cause mortality and cardiovascular outcomes in subjects with an anterior STEMI undergoing pPCI
    Evaluar el efecto de FDY-5301 sobre otros resultados clínicos, como
    mortalidad global y resultados cardiovasculares, en sujetos con IMEST
    anterior sometidos a una ICPp.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Age ≥ 18 years
    2. Anterior STEMI, based on: Symptoms of myocardial ischemia (such as chest pain, shortness of breath, jaw pain, arm pain, diaphoresis, or any anginal equivalent) and ECG criteria:
    • men > 40 years: ≥ 2 mm of ST elevation in V2 and V3
    • men ≤ 40 years: ≥ 2.5 mm of ST elevation in V2 and V3
    • women ≥ 1.5 mm of ST elevation in V2 and V3
    3. Planned primary PCI to occur ≤ 6 hours of onset of first symptoms of myocardial ischemia
    4. Institutional Review Board (IRB) / Independent Ethics Committee (IEC) approved consent obtained for study participation
    1. Edad ≥18 años.
    2. IMEST anterior, basado en:
    Síntomas de isquemia miocárdica (como dolor torácico, disnea, dolor mandibular, dolor en el brazo, diaforesis o cualquier equivalente anginoso) y Criterios electrocardiográficos:
    • Varones >40 años: ≥2 mm de elevación del segmento ST en V2 y V3.
    • Varones ≤40 años: ≥2,5 mm de elevación del segmento ST en V2 y V3.
    • Mujeres: ≥1,5 mm de elevación del segmento ST en V2 y V3.
    3. Previsión de practicar la ICPp en un plazo no superior a 6 horas desde la aparición de los primeros síntomas de isquemia miocárdica
    4. Obtención del consentimiento aprobado por el Comité de Ética de la Investigación con medicamentos (CEIm) para participar en el estudio.
    E.4Principal exclusion criteria
    1. Life expectancy of less than 1 year due to non-cardiac pathology
    2. Known thyroid disease or thyroid disorder, including subjects on thyroid hormone replacement therapy at the time of randomization
    3. Known allergy to iodine
    4. Renal disease requiring dialysis
    5. Women who are pregnant or breastfeeding. Women of reproductive potential must have a negative pregnancy test prior to randomization
    6. Body weight >140 kg (or 309 lbs)
    7. Use of thrombolytic therapy as treatment for the index STEMI event
    8. Use of investigational drugs or devices 30 days prior to randomization
    9. Any clinically significant abnormality identified prior to randomization that in the judgment of the Investigator or Sponsor would preclude safe completion of the study, or confound the anticipated benefit of FDY-5301
    1. Esperanza de vida inferior a un año debido a enfermedades extracardíacas.
    2. Enfermedad o trastorno tiroideo conocido, incluidos los sujetos que estén recibiendo tratamiento de reposición con hormonas tiroideas en el momento de la aleatorización.
    3. Alergia conocida al yodo.
    4. Nefropatía con necesidad de diálisis.
    5. Mujeres embarazadas o en período de lactancia. Las mujeres con capacidad de procrear deberán dar negativo en una prueba de embarazo realizada antes de la aleatorización.
    6. Peso corporal >140 kg.
    7. Uso de tratamiento trombolítico para el episodio de IMEST de referencia.
    8. Uso de fármacos o dispositivos experimentales en los 30 días previos a la aleatorización
    9. Cualquier anomalía clínicamente significativa identificada antes de la aleatorización que, en opinión del investigador o promotor, pueda impedir la finalización segura del estudio o confundir la interpretación de los beneficios previstos de FDY-5301.
    E.5 End points
    E.5.1Primary end point(s)
    The proportion of subjects who experience either cardiovascular mortality (defined as deaths which are sudden and due to presumed arrhythmia, or deaths due to presumed or confirmed thromboembolic CVA, presumed or confirmed pulmonary embolism, cardiac rupture, heart failure, recurrent myocardial infarction [e.g., remote or stent thrombosis], and deaths due to procedural efforts to treat these defined cardiac events), or a heart failure event through Month 12
    Proporción de sujetos con muerte de origen cardiovascular (definida como muertes súbitas y debidas a una presunta arritmia, muertes por accidente cerebrovascular tromboembólico presunto o confirmado, embolia pulmonar presunta o confirmada, rotura cardíaca, insuficiencia cardíaca o infarto de miocardio recurrente [p. ej., trombosis remota o de endoprótesis] y muertes debidas a los procedimientos para tratar estos episodios cardíacos definidos) o un episodio de insuficiencia cardíaca hasta el mes 12.
    E.5.1.1Timepoint(s) of evaluation of this end point
    through month 12
    hasta el mes 12.
    E.5.2Secondary end point(s)
    •The proportion of subjects who experience either all-cause mortality or a heart failure event through Month 12
    •The total number of cardiovascular events defined as cardiovascular mortality and heart failure events through Month 12
    •The proportion of subjects who experience specified non-fatal cardiovascular events of thromboembolic cerebral vascular accident (CVA), ventricular aneurysm/hemorrhage, recurrent myocardial infarction (e.g., remote or stent thrombosis), or persistent arrhythmia through Month 12
    •Serum troponin T at Day 3
    • Proporción de sujetos con muerte por cualquier causa o un episodio de insuficiencia cardíaca hasta el mes 12.
    • Número total de episodios cardiovasculares, definidos como muertes de origen cardiovascular y episodios de insuficiencia cardíaca hasta el mes 12.
    • Proporción de sujetos que presenten episodios cardiovasculares no mortales especificados de accidente cerebrovascular (ACV) tromboembólico, aneurisma o hemorragia ventricular, infarto de miocardio recurrente (p. ej., trombosis remota o de endoprótesis) o arritmia persistente, hasta el mes 12.
    • Concentración sérica de troponina T el día 3.
    E.5.2.1Timepoint(s) of evaluation of this end point
    see E.5.2 for evaluation timing
    ver E.5.2 para el tiempo de evaluación
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic Yes
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned15
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA67
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Canada
    Czechia
    Germany
    Hungary
    Israel
    Italy
    Netherlands
    Poland
    Portugal
    Slovakia
    Spain
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    UVUS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years3
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 500
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 1800
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception For clinical trials recorded in the database before the 10th March 2011 this question read: "Women of childbearing potential" and did not include the words "not using contraception". An answer of yes could have included women of child bearing potential whether or not they would be using contraception. The answer should therefore be understood in that context. This trial was recorded in the database on 2021-12-07. Yes
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation Yes
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    In case subject is not able to give consent - emergency situation (STEMI) and if allowed by regulations LAR can sign the informed consent form on behalf of the subject. The subject will sign the full consent form as soon as the condition has improved
    Encasodeqelsujetonopuedadarsuconsentimiento-stuacióndemergencia(IMEST)ysiregulacioneslopermiten,LARpuedefirmarelformulariodeconsentimientoinformadoennombredelsujeto.Elsujetofirmaráel frmulariodecnsentimientocmpletotnprontocomolacondiciónhayamjorado.
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state220
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 1600
    F.4.2.2In the whole clinical trial 2300
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Ninguno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2022-02-21
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2022-01-11
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 26 18:00:23 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA